Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSI-045B in healthy volunteers and atopic dermatitis patients
NCT05114889Phase 1Completed
- Sponsor
- Biosion
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bosakitug in atopic dermatitis (AD) (8 cohorts), sponsored by Biosion. Primary endpoints: Treatment-Emergent Adverse Events at 17 weeks, Laboratory Tests at 17 weeks and 2 more. Started Oct 2021; status: completed.
02
Drugs
bosakitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05114889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114889.